AbstractPlasma cell microaggregates detected by CD138 immunohistology were demonstrated in 22% of patients achieving morphologic remission 3 months after high-dose therapy for myeloma. Microaggregates were predictive of earlier disease progression, indicating that immunohistology may represent a useful tool in the assessment of minimal disease in patients after high-dose therapy for myeloma.
Figures & Tables
Vol. 90 No. 8 (2005): August, 2005 : Letters to the Editor
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com